CYTOKINETICS, INCORPORATED Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CYTOKINETICS, INCORPORATED stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $4.34M, a 50.99% increase year-over-year.
- CYTOKINETICS, INCORPORATED stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $2.88M, a 7.43% increase year-over-year.
- CYTOKINETICS, INCORPORATED stock issued during period, value, employee stock purchase plan for the quarter ending 2024-06-30 was $2.68M, a 11.54% increase year-over-year.
- CYTOKINETICS, INCORPORATED stock issued during period, value, employee stock purchase plan for the quarter ending 2023-06-30 was $2.40M, a 55.91% increase year-over-year.
- CYTOKINETICS, INCORPORATED stock issued during period, value, employee stock purchase plan for fiscal 2025 was $4.83M, a 4.75% increase from fiscal 2024.
- CYTOKINETICS, INCORPORATED stock issued during period, value, employee stock purchase plan for fiscal 2024 was $4.61M, a 11.30% increase from fiscal 2023.
- CYTOKINETICS, INCORPORATED stock issued during period, value, employee stock purchase plan for fiscal 2023 was $4.14M, a 28.29% increase from fiscal 2022.
- CYTOKINETICS, INCORPORATED stock issued during period, value, employee stock purchase plan for fiscal 2022 was $3.23M, a 81.50% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $4.34M 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $4.83M 10-K · filed 2026-02-26 | |
| 2025-06-30 | $2.88M 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $4.61M 10-K · filed 2026-02-26 | |
| 2024-06-30 | $2.68M 10-Q · filed 2025-11-05 | |
| 2023-12-31 | $4.14M 10-K · filed 2026-02-26 | |
| 2023-06-30 | $2.40M 10-Q · filed 2024-11-07 | |
| 2022-12-31 | $3.23M 10-K · filed 2025-02-27 | |
| 2022-06-30 | $1.54M 10-Q · filed 2023-11-03 | |
| 2021-12-31 | $1.78M 10-K · filed 2024-02-28 | |
| 2021-06-30 | $969.00K 10-Q · filed 2022-11-04 | |
| 2020-12-31 | $1.51M 10-K · filed 2023-03-01 | |
| 2020-06-30 | $826.00K 10-Q · filed 2021-11-05 | |
| 2019-12-31 | $1.11M 10-K · filed 2022-02-25 | |
| 2019-06-30 | $548.00K 10-Q · filed 2020-11-06 | |
| 2018-12-31 | $392.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $928.00K 10-K · filed 2021-02-26 |
| 2018-06-30 | $536.00K 10-Q · filed 2019-11-01 | |
| 2017-12-31 | $1.17M 10-K · filed 2019-03-07 | |
| 2016-12-31 | $917.00K 10-K · filed 2018-03-05 | |
| 2015-12-31 | $69.00K 10-K · filed 2018-03-05 | |
| 2014-12-31 | $67.00K 10-K · filed 2017-03-06 | |
| 2013-12-31 | $55.00K 10-K · filed 2016-03-03 | |
| 2012-12-31 | $65.00K 10-K · filed 2015-03-06 | |
| 2011-12-31 | $6.13M 10-K · filed 2014-03-07 | |
| 2010-12-31 | $228.00K 10-K · filed 2013-03-15 | |
| 2009-12-31 | $249.00K 10-K · filed 2013-03-15 | |
| 2008-12-31 | $468.00K 10-K · filed 2013-03-15 | |
| 2007-12-31 | $807.00K 10-K · filed 2013-03-15 | |
| 2006-12-31 | $856.00K 10-K · filed 2013-03-15 | |
| 2005-12-31 | $763.00K 10-K · filed 2013-03-15 | |
| 2004-12-31 | $557.00K 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |